New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches

This study describes the synthesis and biological activity of new imadazopyrazines as first-in-class CDK9 inhibitors. The inhibition of CDK9 is a well-established therapeutic target in cancer therapy. The new compounds were assessed using an in vitro kinase assay against CDK9. In this assay, compoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsfouk, Aisha A., Alshibl, Hanan M., Altwaijry, Najla A., Alanazi, Ashwag, AlKamaly, Omkulthom, Sultan, Ahlam, Alsfouk, Bshra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383573/
https://www.ncbi.nlm.nih.gov/pubmed/37513929
http://dx.doi.org/10.3390/ph16071018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383573/
https://www.ncbi.nlm.nih.gov/pubmed/37513929
http://dx.doi.org/10.3390/ph16071018

Ejemplares similares